Fritextsökning
Artiklar per år
Innehållstyper
-
19 medicines in Sweden are under investigation in a major EMA inquiry
19 medicines marketed in Sweden are affected by an ongoing extensive European investigation into suspected fraud at an Indian contract research organisation. Among them are medicines for HIV, epilepsy, cancer and Parkinson’s, which may be withdrawn
-
Samuel Lagercrantz: A special kind of hellishness afflicts post-COVID patients
In addition to the disease itself those suffering from post-COVID have to deal with people who try to label them as hypochondriacs, writes Samuel Lagercrantz in an editorial.
-
Petter Brodin får pris för forskning inom pediatriken
KI-professorn och barnläkaren, Petter Brodin tilldelas Oscar Medins pris 2023 av Svenska Läkaresällskapet.
-
Heidi Stensmyren is eager for new challenges in the biotech industry
Heidi Stensmyren has served as President of the Swedish Medical Association, held a managerial position at Karolinska University Hospital and is now Medical Director at a biotech company. “I’m curious and like to have influence, so I’ve often chosen management roles,” she says.
-
Abliva får snabbspår i USA – aktien tog glädjeskutt
Lundabolaget Ablivas främsta läkemedelskandidat har beviljats så kallad Fast Track Designation, ett snabbspår, i USA.
-
Petter Hartman: ”Stora ord och höga ambitioner”
”Man får sannerligen hoppas att våra folkvalda är införstådda med allvaret när förslaget debatteras”, skriver Petter Hartman i en krönika om förslaget på en ny läkemedelslagstiftning för EU.
-
CROs in drug development: "We use our expertise to speed up the process
Consultancy firms have become an increasingly important part of drug development. “It’s a trend and a business model that works, and we see no indication that it will change,” says Helena Lüning of the industry organisation ASCRO.
-
Why the world renown researcher Marc Tessier-Lavigne resigns as Stanford´s president
In mid-summer, neuroscientist Marc Tessier-Lavigne announced his resignation as President of Stanford following allegations of manipulated study data. According to the reporter Theo Baker, who first reported the story, Tessier-Lavigne “rewarded the winners and punished the losers”. Here is the background of the story which has shaken the American scientific community over the summer.
-
The Swedish Life Science Office: “We lost in both coordination and manpower”
Since the turn of the year, the Swedish government’s life science office has operated at a lower capacity. Life Science Sweden has spoken to Pontus Holm, Departmental Secretary at the office, about the ongoing work.
-
Neanderthal gene variants may cause Viking disease
A new study suggests that the so-called Viking disease, which affects the hand function in many older people, may be linked to gene variants inherited from Neanderthals.
-
Lucy Robertshaw: Artificial intelligence – is this really going to transform a patient’s life?
In a column Lucy Robertshaw reflects on how AI and new regulations will affect healthcare, innovation and the lives of future patients.
-
Novo Nordisk invests billions in expanding its production capacity
Danish pharmaceutical company Novo Nordisk is making a major investment to develop and expand its production facility in Hillerød, north of Copenhagen. DKK 15.9 billion, equivalent to almost SEK 25 billion, is being invested over six years.
-
Novo Nordisk mångmiljardsatsar för att utöka produktionen
Det danska läkemedelsbolaget Novo Nordisk gör en storsatsning på att utveckla och utöka sin produktion i Hillerød, norr om Köpenhamn. 15,9 miljarder danska kronor, motsvarande nästan 25 miljarder svenska kronor, investeras under sex år.
-
Getinge stärker närvaron på läkemedelsområdet i miljardaffär
Getinge förvärvar amerikanska High Purity New England, som tillverkar engångsprodukter för bioprocesser. Den svenska medtech-jätten betalar närmare 1,3 miljarder direkt, men affären kan växa till att kliva över tremiljarderstrecket.
-
Anocca tar in 400 miljoner – ska ta första produkterna till klinisk prövning
Cellterapibolaget Anocca tar in 400 miljoner i en nyemission som ska bidra till att ta bolagets första cancerbehandlingar till klinisk prövning.
-
Norwegian company wins bidding battle for Sensidose
The lengthy battle to acquire medical device company Sensidose is apparently over. Generic medicines company EQL Pharma is pulling out, selling its shares and leaving the way open for Norwegian company Navamedic.
-
Samuel Lagercrantz: The government’s performance in healthcare and life sciences so far
Since the change of government in Sweden, developments in the healthcare sector have shown promising signs, but the outlook in life sciences is less promising, writes Samuel Lagercrantz in an editorial.
-
Ny finanschef på Synact Pharma
Biotechbolaget Synact Pharma rekryterar meriterade Björn Westberg till rollen som Chief Financial Officer och medlem av koncernledningen.
-
The first Lyme disease vaccine faces a delay
Pfizer and Valneva’s Lyme disease vaccine, which could be the first of its kind, is facing delays of about a year. The reason is problems at trial sites in the United States, which have forced the companies to drop half of the participants in an ongoing Phase III study.
-
Borreliavaccin försenas efter strul med studie
Pfizers och Valnevas borreliavaccin, som kan bli det första i sitt slag, försenas med åtminstone ett år. Orsaken är problem vid prövningssajter i USA som tvingat bolagen att stryka hälften av deltagarna i en pågående fas III-studie.
-
Grönt ljus från EMA för första vaccinet mot RS-virus
EU har tagit ett stort steg mot ett erkännande av det första vaccinet mot RS-virus, avsett för personer som är 60 år eller äldre.
-
New report: Fewer PhDs in life sciences
A new report from Vinnova suggests that competency returns in the life science sector are declining.
-
Confidence in childhood vaccines is in decline worldwide
Since the pandemic, confidence in vaccinating children has plummeted. In a new report, UNICEF urges world leaders to act before the situation worsens. In 52 out of 55 countries surveyed, public perception of the importance of vaccinating children has declined.
-
New diagnostic rules raise concerns
In a panel discussion, several voices from academia and the industry expressed concerns about the transition to the new regulatory framework for in-vitro diagnostics (IVDR). They argue that it may create significant differences between regions
BREAKING